Oral anticoagulation in patients with cardiomyopathy or heart failure in sinus rhythm

Cerebrovascular Diseases

Volumn 26, Issue 3, 2008, Pages 322-327

  Pullicino, P ^a,b   Thompson, J L P ^c,d   Mohr, J P ^d   Sacco, R L ^e   Freudenberger, R ^f   Levin, B ^c   Homma, S ^d  

^a UNIVERSITY OF KENT   (United Kingdom)

^b INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^c Mailman School of Public Health   (United States)

^d Howard Hughes Medical Institute   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Heart failure, anticoagulation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; IRBESARTAN; PLACEBO; WARFARIN;

ANGIOCARDIOGRAPHY; ANTICOAGULATION; BRAIN HEMORRHAGE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EMBOLISM; FATIGUE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART STROKE VOLUME; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERNATIONAL NORMALIZED RATIO; PATHOGENESIS; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SCINTISCANNING; SINUS RHYTHM; STROKE; STROKE PATIENT; THROMBOEMBOLISM; TREATMENT INDICATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOMYOPATHIES; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 48049116412     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000149581     Document Type: Review

References (35)

1. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL: The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-531.
2. Katz SD, Marantz PR, Biasucci L, Jondeau G, Lee K, Brennan C, LeJemtel TH: Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993;126:141-146.
3. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ: Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074-1080.
4. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, Roger VL: Ischemic stroke after heart failure: a community-based study. Am Heart J 2006;152:102-109.
5. Pullicino P, Thompson JLP, Barton B, Levin B, Graham S, Freudenberger RS, WARCEF Investigators: Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives and design. J Cardiac Fail 2006;12:39-46.
6. Mosterd A, Hoes AW, De Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE: Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999;20:447-455.
7. Han SW, Nam HS, Kim SH, Lee JY, Lee K-Y, Heo JH: Frequency and significance of cardiac sources of embolism in the TOAST classification. Cerebrovasc Dis 2007;24:463-468.
8. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
9. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987;147:1561-1564.
10. Kannel WB, Wolf PA, Verter J: Manifestations of coronary disease predisposing to stroke: the Framingham study. JAMA 1983;250:2942-2946.
11. Loh E, Sutton MSJ, Wun CCC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moyé LA, Goldhaber SZ, Pfeffer MA: Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
12. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S: The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. J Cardiac Fail 2004;10:101-112.
13. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO: Survival and recurrence after first cerebral infarction - a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208-216.
14. Sacco RL, Shi T, Zamanillo MC, Kargman DE: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626-634.
15. Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, Mark DB, Lee KL, Bardy GH, the SCD-HeFT Investigators: Risk factors for thromboembolism in the SCD-Heft Study. Circulation 2007;115:2637-2641.
16. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, Homma S, Di Tullio MR: Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006;37:1715-1719.
17. Atrial Fibrillation Investigators: Echocardiographic predictors of stroke in patients with atrial fibrillation. Arch Intern Med 1998;158:1316-1320.
18. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG: Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998;31:1622-1626.
19. Handke M, Harloff A, Hetzel A, Olschewski M, Bode C, Geibel A: Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation - a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr 2005;18:1366-1372.
20. Griffith GC, Stragnell R, Levinson DC, Moore FJ, Waare AG: A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952;37:867-887.
21. Anderson GM, Hull E: The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 1950;39:697-702.
22. Harvey WP, Finch CA: Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950;242:208-211.
23. Kyrle PA, Korninger C, Gossinger H, Glogar D, Lechner K, Niessner H, Pabinger I: Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985;54:521-523.
24. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
25. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P, the WARSS study group: Warfarin-aspirin recurrent stroke study (WARSS). N Engl J Med 2001;345:1444-1451
26. The ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for the Prevention of Vascular Events (ACTIVE-W): a randomised controlled trial. Lancet 2006;367:1903-1912.
27. Hirsh J, Fuster V, Ansell J, Halperin J: AHA/ACC scientific statement: American Heart Association/American College of Cardiology foundation guide to warfarin therapy. Circulation 2003;107:1692-1711.
28. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic treatment for ischemic stroke: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:483S-512S.
29. Hacke W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, Leys D, Kwiecinski H, Toni P, Langhorne P, Diener C, Hennerici M, Ferro J, Sivenius J, Gunnar N, Bath P, Olsen TS, Gugging M, European Stroke Initiative Executive Committee and the EUSI Writing Committee: European Stroke Initiative recommendations for stroke management - update. Cerebrovasc Dis 2003;16:311-337.
30. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA: The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-164.
31. Meschia JF, Brott TG, Chukwudelunzu FE, Hardy J, Brown RD Jr, Meissner I, Hall LJ, Atkinson EJ, O'Brien PC: Verifying the stroke-free phenotype by structured telephone interview. Stroke 2000;31:1076-1080.
32. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;31:749-753.
33. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
34. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-2150.
35. Saver JL: Number needed to treat estimates incorporating effects over the entire range of clinical outcomes. Arch Neurol 2004;61:1066-1070.